Pharmacia Corporation / Sensus Drug Development Corporation

Acromegaly

3K US cases/yr

Disease Overview

Acromegaly is a rare, slowly progressive endocrine disorder caused in >95% of cases by a growth hormone-secreting pituitary adenoma, leading to excess GH and IGF-1, characteristic skeletal/soft-tissue overgrowth, cardiovascular and metabolic complications, and elevated mortality if untreated. It typically affects adults and is diagnosed years after symptom onset.

Competitive Landscape

At the time Pharmacia exercised its option for the remainder of Sensus in March 2001, the acromegaly treatment landscape was dominated by surgical resection of pituitary adenomas as first-line therapy, with medical treatment driven by somatostatin analogs — Novartis's Sandostatin (octreotide) and its long-acting depot Sandostatin LAR, soon followed by Ipsen's Somatuline (lanreotide) — plus older dopamine agonists (bromocriptine, cabergoline). All of these acted upstream by suppressing GH secretion, but a meaningful subset of patients (~30-40%) failed to normalize IGF-1. Pegvisomant (Somavert) was a fundamentally different mechanism: a PEGylated GH analog that competitively antagonized the GH receptor itself, normalizing IGF-1 even in somatostatin-refractory disease. For Pharmacia the strategic logic was clean: it already marketed Genotropin (somatropin) to endocrinologists, so Somavert plugged into an existing physician network and sales infrastructure, and orphan-drug status with priority review meant fast, defensible launch economics. Sensus had filed the NDA in February 2001; an approvable letter arrived in July 2001 and FDA approval followed in 2003. Pharmacia was acquired by Pfizer in 2003, which carried Somavert forward as a durable rare-disease franchise asset.